Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+Treg cells and inducing Th1 to Th2 shift in both cells and cytokines

Biomedicine and Pharmacotherapy

Volumn 64, Issue 7, 2010, Pages 463-471

  Xinqiang, Song ^a   Fei, Liang ^a   Nan, Liu ^a   Yuan, Luo ^a   Fang, Yuan ^a   Hong, Xue ^a   Lixin, Tan ^a   Juan, Long ^a   Xiao, Zhao ^a   Yuying, Sun ^a   Yongzhi, Xi ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Collagen induced arthritis; Immunosuppression; Immunotolerance; Low dose methotrexate; Rheumatoid arthritis

Indexed keywords

CD4 ANTIGEN; COLLAGEN TYPE 2; CYTOKINE; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TH1 CELL; TH2 CELL; X RAY ANALYSIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CD4 LYMPHOCYTE COUNT; COLLAGEN TYPE II; CYTOKINES; FEMALE; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; METHOTREXATE; RATS; RATS, WISTAR; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH2 CELLS;

EID: 77955138747     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.01.007     Document Type: Article

References (61)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 15(423(6937)):356-361.
2. Wildbaum G., Nahir M.A., Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003, 19(5):679-688.
3. Sinha A.A., Lopez M.T., McDevitt H.O. Autoimmune diseases: the failure of self tolerance. Science 1990, 248:1380-1388.
4. O'Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004, 10:801-805.
5. Feldmann M. Pathogenesis of arthritis: recent research progress. Nat Immunol 2001, 2:771-773.
6. Friend D.S., Gurish M.F., Benoist C., et al. Mast Cells: A cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-1692.
7. Liew F.Y., McInnes I.B. A fork in the pathway to inflammation and arthritis. Nat Med 2005, 11:601-602.
8. von Herrath M.G., Harrison L.C. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003, 3:223-232.
9. Hirano T. Revival of the autoantibody model in rheumatoid arthritis. Nat Immunol 2002, 3:342-344.
10. Steinman L. Immune therapy for autoimmune diseases. Science 2004, 305:212-216.
11. Rodan G.A., Martin T.J. Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
12. Feldmann M., Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005, 435:612-619.
13. Feldmann M., Maini R.N. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003, 9:1245-1250.
14. Mayer L., Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol 2004, 4:407-419.
15. Mainni R.N., Taylor P.C. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000, 51:207-229.
16. Xu H., Xi Y.Z. Perspectives in gene therapy for autoimmune diseases. Nat Med J China 2006, 86:933-935.
17. Sokka T., Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 2002, 29(12):2521-2524.
18. Swierkot J., Szechinski J. Methotreate in rheumatoid arthritis. Pharmacol Rep 2006, 58:473-492.
19. Cronstein B. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005, 57:163-172.
20. Pincus T., Yazici Y., Sokka1 T., Aletaha D., Smolen J.S. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003, 21(Suppl. 31):S179-S185.
21. van der Heijden J.W., Dijkmans B.A.C., Scheper R.J., Jansen G. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs-from bench to bedside. Nat Clin Pract Rheumatol 2007, 3(1):26-34.
22. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54(1):26-37.
23. van der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54(4):1063-1074.
24. Weaver A.L., Lautzenheiser R.L., Schiff M.H., Gibofsky A. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006, 22(1):185-198.
25. Pavy S., Constantin A., Pham T., Gossec L. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73(4):388-395.
26. Stamp L., Roberts R., Kennedy M., Barclay M. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?. Biomed Pharmacother 2006, 60(10):678-687.
27. Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999, 11(3):226-232.
28. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4(4):266-273.
29. Herman S., Zurgil N., Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005, 54(7):273-280.
30. Herman S., Zurgil N., Langevitz P. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunol Invest 2004, 33(3):351-362.
31. Johnston A., Gudjonsson J.E., Sigmundsdottir H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 2005, 114(2):154-163.
32. Genestier L., Paillot R., Fournel S. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998, 15(102[2]):322-328.
33. Fairbanks L.D., Ruckemann K., Qiu Y. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis?. Biochem J 1999, 15(342 [Pt 1]):143-152.
34. Budzik G.P., Colletti L.M., Faltynek C.R. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line. Life Sci 2000, 66(23):2297-2307.
35. Gerards A.H., de Lathouder S., de Groot E.R. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(10):1189-1196.
36. Kraan M.C., Smeets T.J., van Loon M.J. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004, 63(9):1056-1061.
37. De A., Blotta H.M., Mamoni R.L. Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis. J Rheumatol 2002, 29(1):46-51.
38. Morita Y., Fukazawa T., Hirashima M. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006, 35(4):268-272.
39. Schuerwegh A.J., van Offel J.F., Bridts C.H. Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis. J Rheumatol 2001, 28(8):1793-1799.
40. Kane D., Gogarty M., O'leary J. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004, 50(10):3286-3295.
41. Trentham D.E., Dynesius-Trentham R.A., Orav E.J., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993, 261:1727-1730.
42. Barnett M.L., Combitchi D., Trentham D.E. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:623-628.
43. Barnett M.L., Kremer J.M., St Clair E.M., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998, 41:290-297.
44. Sieper J., Kary S., Sorensen H., et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996, 39:41-51.
45. Rosloniec EF, Kang AH, Myers LK, et al. Collagen-induced arthritis. In: Coico R, Shevach E, editors. Current protocols in immunology. New York: Wiley & Sons; 1997. p. 1-24.
46. Morgan S.L., Baggott J.E., Bernreuter W.K., et al. MTX affects inflammation and tissue destruction differently in the rat AA model. J Rheumatol 2001, 28(7):1476-1481.
47. Cuzzocrea S., Mazzon E., di Paola R. Synergistic interaction between methotrexate and a superoxide dismutase mimetic: pharmacologic and potential clinical significance. Arthritis Rheum 2005, 52:3755-3760.
48. Paimela L., Laasonen L., Helve T., et al. Comparison of the original and the modified Larsen methods and the Sharp method in scoring radiographic progression in early rheumatoid arthritis. J Rheumatol 1998, 25:1063-1066.
49. Williams P.J., Jones R.H., Rademacher T.W. Correlation between IgG anti-type II collagen levels and arthritic severity in murine arthritis. Autoimmunity 1998, 27:201-207.
50. Lange F., Bajtner E., Rintisch C., Nandakumar K.S., Sack U., Holmdahl R. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis. Ann Rheum Dis 2005, 64:599-605.
51. Mukherjee P., Wu B., Mayton L., Kim S.H., Robbins P.D., Wooley P.H. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis 2003, 62(8):707-714.
52. Kim W.U., Cho M.L., Jung Y.O., et al. Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 2004, 327:202-211.
53. Winkelstein A., Simon P.L., Myers P.A., Weaver L.D. Comparisons of 12-tetradecanoylphorbol-13-acetate (TPA) and PHA as mitogens in the T-lymphocyte colony assay. Exp Hematol 1986, 14(11):1023-1028.
54. Toh M.L., Miossec P. The role of T cells in rheumatoid arthritis: new subsets and new targets. Curr Opin Rheumatol 2007, 19(3):284-288.
55. Mekala D.J., Geiger T.L. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 2005, 105(5):2090-2092.
56. Yamaki K., Uchida H., Harada Y Effect of methotrexate on Th1 and Th2 immune responses in mice. J Pharm Pharmacol 2003, 55(12):1661-1666.
57. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 11(441[7090]):231-234.
58. de Lathouder S., Gerards A.H., de Groot E.R. Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. Eur Cytokine Netw 2002, 13(3):317-323.
59. Neurath M.F., Hildner K., Becker C., Schlaak J.F., Barbulescu K., Germann T., et al. Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1999, 115(1):42-55.
60. Kazuo Y., Hiroaki M., Fujio N., et al. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum 2000, 43:617-627.
61. Masuko H.K., Kato T., Nishioka K. Prognostic value of Th1/Th2 ratio in rheumatoid arthritis. Lancet 1998, 352:988-999.